{"id":"W4395689019","doi":"10.1038/s41375-024-02254-2","title":"The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network","year":2024,"lang":"en","type":"article","venue":"Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"MSD K.K.; Bristol-Myers Squibb Canada; Sanofi-Aventis Korea Company; Servier; Miltenyi Biotec; Takeda Pharmaceutical Company; AbbVie; Janssen Pharmaceuticals; Gilead Sciences; Roche; Novartis; Merck; GlaxoSmithKline; Celgene; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; Falk Foundation","keywords":"Mantle cell lymphoma; Medicine; Bortezomib; Leukocytopenia; Internal medicine; Cytarabine; Rituximab; Autologous stem-cell transplantation; Neutropenia; Oncology; Gastroenterology; Surgery; Chemotherapy; Multiple myeloma; Lymphoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001893691,0.0003443582,0.001092125,0.0001152885,0.0001574,0.00008602094,0.000377935,0.0001296429,0.00009145386],"category_scores_gemma":[0.0002167787,0.0001831159,0.0001815042,0.0005676287,0.0002389033,0.0001067954,0.0003196268,0.0001326149,0.00004422927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007236865,"about_ca_system_score_gemma":0.0006992242,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001241355,"about_ca_topic_score_gemma":0.0001607023,"domain_scores_codex":[0.9968788,0.0007623877,0.001006815,0.0005311777,0.0004147175,0.0004060914],"domain_scores_gemma":[0.9970047,0.001631157,0.0003393844,0.0007809355,0.00007695063,0.0001668482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7881023,0.01029392,0.0000739894,0.0003729592,0.0004385053,0.0007539705,0.0009223432,0.00004856383,0.004077616,0.0005637624,0.03644485,0.1579072],"study_design_scores_gemma":[0.970598,0.001697565,0.001241283,0.0008253435,0.0006650741,0.00003653469,0.000114161,0.0009301541,0.01034968,0.0001851332,0.01313509,0.0002219074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845836,0.003751102,0.00002525338,0.0005500569,0.000796254,0.003457371,0.0001121931,0.00003875902,0.006685424],"genre_scores_gemma":[0.9933756,0.001768723,0.0006886835,0.0003059309,0.0003549753,0.0002921161,0.00007187969,0.00007031715,0.003071778],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1824957,"threshold_uncertainty_score":0.7467252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01898169825617816,"score_gpt":0.2830004427703793,"score_spread":0.2640187445142012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}